New products
IceCure enrols initial patients for ProSense cryoablation trial in US
IceCure Medical has enrolled the first two patients at two US clinical centers in the ChoICE trial evaluating its ProSense cryoablation system for treatment of low-risk breast cancer. The trial marks an early-stage clinical assessment of the company's ablation device in a breast-cancer indication.
The source
This brief is a MedIndexer summary of reporting by Medical Device Network. To read the full story, head to the source.
Read the full story at Medical Device Network